Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

CUE
Cue Biopharma, Inc.
stock NASDAQ

At Close
Apr 29, 2026 3:59:30 PM EDT
13.00USD+4.376%(+0.55)85,215
11.13Bid   14.82Ask   3.69Spread
Pre-market
Apr 29, 2026 9:16:30 AM EDT
13.10USD+5.179%(+0.65)300
After-hours
Apr 28, 2026 4:38:30 PM EDT
13.14USD+6.053%(+0.75)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 27, 2022
07:58AM EST  The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study   Benzinga
06:53AM EST  Cue Pharma Posts Two Responses From CUE-101 Combo In Head & Neck Cancer   Benzinga
Jan 26, 2022
04:16PM EST  Cue Biopharma Reports Two Objective Responses In First Interim Update From Dose Escalation Portion Of Ongoing Phase 1 Combination Study Of CUE-101 And KEYTRUDA In First Line Patients With HPV+ Recurrent/Metastatic Head And Neck Cancer   Benzinga
04:01PM EST  Cue Biopharma Reports Two Objective Responses(1 cPR   GlobeNewswire Inc
08:29AM EST  The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data   Benzinga
Jan 23, 2022
11:03AM EST  The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More   Benzinga
Jan 20, 2022
08:00AM EST  Cue Biopharma to Host Business Update Call and Webcast for Ongoing   GlobeNewswire Inc
Jan 5, 2022
08:00AM EST  -- Selective activation and expansion of Wilms Tumor 1 (WT1)-specific cytotoxic CD8+T cells in preclinical models supports the potential for clinical activity treating WT1-expressing cancers -- Further advancement of CUE-102 enhances pipeline development and demonstrates modularity of the Immuno-STAT platform for addressing a myriad of cancer antigens   GlobeNewswire Inc
Dec 15, 2021
08:00AM EST  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patients body, announced today the appointment of Patricia Nasshorn, as Chief Business Officer, effective December 15th, 2021.   GlobeNewswire Inc
Dec 6, 2021
08:00AM EST  Cue Biopharma to Present at JMP Securities Hematology and Oncology   GlobeNewswire Inc
Nov 22, 2021
08:00AM EST  Cue Biopharma to Present at the Piper Sandler 33rd Annual   GlobeNewswire Inc
Nov 12, 2021
08:18AM EST  Candel Therapeutics, Cue, Madrigal Pharma, F-star, Aligos, Albireo Pharma, Actinium Highlights Presentations At Society For Immunotherapy Of Cancers Meeting Nov. 12-14, The Liver Meeting   Benzinga
08:14AM EST  Candel Therapeutics, Cue, Madrigal Pharma, Aligos, Albireo Pharma, Actinium Highlights Presentations At Society For Immunotherapy Of Cancers Meeting Nov. 12-14, The Liver Meeting   Benzinga
08:00AM EST  Cue Biopharma Presents Updated Data from Lead Program CUE-101 for   GlobeNewswire Inc
Nov 10, 2021
08:00AM EST  Cue Biopharma to Present at Two UpcomingInvestor   GlobeNewswire Inc
Oct 21, 2021
12:00PM EDT  Cue Biopharma Announces Publication in The Journal of Clinical   GlobeNewswire Inc
Oct 6, 2021
09:16AM EDT  Cue Health Reports Collab With Google Health 'To Add Variant Sequencing, Tracking, And Predictive Capabilities To Its Cue Platform'   Benzinga
Oct 4, 2021
08:00AM EDT  Cue Biopharma Announces Upcoming Scientific Presentations at the   GlobeNewswire Inc
Sep 28, 2021
08:23AM EDT  Cue Biopharma Highlights Publication In Nature Journal, Scientific Reports, Of Immunotherapeutic Platforms Immuno-STAT And Neo-STAT   Benzinga
08:00AM EDT  -- Research demonstrates that platform technologies generate therapeutic molecules for selective delivery of immune activating signals, such as IL-2, to disease-relevant T cells, hence avoiding systemic activation of the broader immune compartment   GlobeNewswire Inc
Sep 21, 2021
08:04AM EDT  Cue Biopharma Reports Granted US Patents On Lead Clinical Program Novel Drug Product Candidate CUE-101   Benzinga
08:00AM EDT  Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the body, announced today the issuance of two new United States Patents Nos. 11,117,945 and 11,104,712 from the United States Patent and Trademark Office.   GlobeNewswire Inc
Sep 9, 2021
08:00AM EDT  Cue Biopharma to Present at Two Upcoming Investor Healthcare   GlobeNewswire Inc
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
04:03PM EDT  Cue Biopharma Q2 EPS $(0.33) Beats $(0.42) Estimate, Sales $2.74M Beat $1.06M Estimate   Benzinga
04:01PM EDT  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patients body, provided a business and clinical progress update for the second quarter 2021.   GlobeNewswire Inc
Aug 10, 2021
08:00AM EDT  Cue Biopharmato Host Business Update Call and Webcast   GlobeNewswire Inc
Aug 3, 2021
08:00AM EDT  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patients body, announced today that it will participate in a fireside chat at the BTIG Virtual Biotechnology Conference being held August 9-10 2021.   GlobeNewswire Inc
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 14, 2021
07:48AM EDT  The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues   Benzinga
Jun 14, 2021
08:00AM EDT  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patients body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held June 16-17, 2021.   GlobeNewswire Inc
Jun 10, 2021
08:01AM EDT  Cue Biopharma Announces First Patient Dosed In Part B Patient Expansion Of CUE-101 Phase 1 Monotherapy Trial In HPV+ Second Line And Beyond HNSCC   Benzinga
08:00AM EDT  Cue Biopharma Announces First Patient Dosed in Part B Patient   GlobeNewswire Inc
Jun 3, 2021
08:30AM EDT  Cue Biopharmato Present at the 2021 Federation of   GlobeNewswire Inc
May 26, 2021
08:00AM EDT  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patients body, announced today that it will present at the Jefferies Virtual Healthcare Conference being held June 1-4, 2021.   GlobeNewswire Inc
May 17, 2021
04:07PM EDT  Cue Biopharma Q1 EPS $(0.41) Misses $(0.38) Estimate, Sales $1.55M Up From $900.00K YoY   Benzinga
04:01PM EDT  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patients body, provided a business and clinical progress update for the first quarter 2021.   GlobeNewswire Inc
04:10AM EDT  Earnings Scheduled For May 17, 2021   Benzinga
May 10, 2021
02:40PM EDT  Mid-Afternoon Market Update: Dow Surges 125 Points; Trade Desk Shares Plunge   Benzinga
01:14PM EDT  Cue Biopharma's Stock Shoots Up After CUE-101 Shows Promise In Early-Stage Head & Neck Cancer Study   Benzinga
12:15PM EDT  Mid-Day Market Update: Nasdaq Drops 200 Points; Soliton Shares Spike Higher   Benzinga
10:00AM EDT  Cue Biopharma to Host Business Update Call and Webcast   GlobeNewswire Inc
08:01AM EDT  Cue Biopharma Reports Confirmed Partial Response In Ongoing Phase 1 Monotherapy Study Of CUE-101 In Late Stage Second Line And Beyond Patients With HPV+ Recurrent/Metastatic Head And Neck Cancer   Benzinga
08:00AM EDT  Cue Biopharma Reports Confirmed Partial Response (PR) in Ongoing   GlobeNewswire Inc
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 6, 2021
08:00AM EDT  Cue Biopharmato Present at the 2021 Frontiers in   GlobeNewswire Inc
Mar 16, 2021
04:03PM EDT  Cue Biopharma Q4 EPS $(0.37) Misses $(0.35) Estimate   Benzinga
04:01PM EDT  Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial   GlobeNewswire Inc
08:17AM EDT  The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study   Benzinga
Mar 15, 2021
08:06AM EDT  Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference   Benzinga
08:00AM EDT  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patients body, announced today that it will present at the virtual Oppenheimer 31st Annual Healthcare Conference being held March 16-18, 2021.   GlobeNewswire Inc
Mar 14, 2021
08:14AM EDT  Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations   Benzinga
Mar 9, 2021
08:00AM EST  Cue Biopharmato Host Business Update Call and Webcast   GlobeNewswire Inc
Mar 1, 2021
08:00AM EST  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patients body, announced today that it will present at the Cowen 41st Annual Health Care Conference being held virtually from March 1-4, 2021.   GlobeNewswire Inc
Feb 25, 2021
08:00AM EST  Cue BiopharmaEnhances Scientific Advisory Board with   GlobeNewswire Inc
Feb 22, 2021
08:00AM EST  Cue Biopharmato Present at the 7th Annual   GlobeNewswire Inc
Feb 17, 2021
08:00AM EST  Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs   GlobeNewswire Inc
Feb 8, 2021
08:31AM EST  Cue Biopharma Initiates Patient Dosing In Phase 1 Study Of CUE-101 In Combination with KEYTRUDA As First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer   Benzinga
08:00AM EST  Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101   GlobeNewswire Inc
Nov 24, 2020
09:51AM EST  Benzinga's Top Upgrades, Downgrades For November 24, 2020   Benzinga
08:42AM EST  Berenberg Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $30   Benzinga
Nov 23, 2020
08:00AM EST  Cue Biopharma to Present at the Piper Sandler 32nd Annual   GlobeNewswire Inc
Nov 19, 2020
08:27AM EST  Cue Biopharma Extends Research Collaboration For The Development Of Immuno-STAT Biologics For The Treatment Of Defined Autoimmune Diseases With Merck   Benzinga
08:00AM EST  Cue Biopharma Extends Research Collaboration for the Development   GlobeNewswire Inc
Nov 17, 2020
04:04PM EST  Cue Biopharma PR Shows Q3 EPS $(0.34) Down From $(0.31) YoY, Sales $704.00K Down From $984.00K YoY; Results Were Out Last Week In A Filing   Benzinga
04:01PM EST  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patients body, provided a business update for the third quarter of 2020.   GlobeNewswire Inc
Nov 12, 2020
07:44AM EST  The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal   Benzinga
Nov 11, 2020
08:00AM EST  Cue Biopharma to Present at Upcoming Investor Conferences in   GlobeNewswire Inc
Nov 10, 2020
08:00AM EST  Cue Biopharmato Host Business Update Call and Webcast   GlobeNewswire Inc
Nov 9, 2020
08:05AM EST  Cue Biopharma Announces Presentations Highlighting Clinical Progress Of CUE-101, Pipeline Progress Of CUE-100 Series Immuno-STATs And Immuno-STAT Data For Infectious Disease Applications At The Society For Immunotherapy Of Cancer's (SITC) 35th Anniversary   Benzinga
08:01AM EST  Cue Biopharma Announces Presentations Highlighting Clinical   GlobeNewswire Inc
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Oct 19, 2020
08:00AM EDT  Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today three poster presentations at the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting (SITC 2020).   GlobeNewswire Inc
Sep 17, 2020
08:15AM EDT  Cue Biopharma Appoints Tamar Howson To Its Board   RTTNews
08:00AM EDT  Appointment augments board capabilities with a seasoned business development executive asCue Biopharma executes its next stage of corporate development   GlobeNewswire Inc
Sep 15, 2020
08:17AM EDT  Cue Biopharma Highlights Nature Methods Publication Of Preclinical Data Showing Tumor Penetration And Antigen-Specific T Cell Engagement With Immuno-STAT Based Protein Scaffolds   Benzinga
08:00AM EDT  Novel positron emission tomography approach demonstrates the ability of Immuno-STAT based scaffolds to selectively engage tissue-resident T cells including intratumoral T cells of defined specificity   GlobeNewswire Inc
Sep 3, 2020
08:00AM EDT  Cue Biopharma to Present at Upcoming Investor Conferences in   GlobeNewswire Inc
Aug 31, 2020
04:03PM EDT  Cue Biopharma Publishes Press Release For Previously Released Q2 Results   Benzinga
04:01PM EDT  Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, provided a business update for the second quarter of 2020.   GlobeNewswire Inc
Aug 30, 2020
08:24AM EDT  The Week Ahead In Biotech (Aug. 30- Sept. 5): Bristol-Myers Squibb FDA Decision, Adcom Review For Glaxo, Amarin Vascepa Hearing   Benzinga
Aug 24, 2020
08:00AM EDT  Cue Biopharmato Present at the 16th Annual PEGS Boston   GlobeNewswire Inc
Aug 17, 2020
08:00AM EDT  Cue Biopharmato Host Business Update Call and Webcast   GlobeNewswire Inc
Jul 28, 2020
08:03AM EDT  Cue Biopharma Begins Dosing Cohort 5 In An Ongoing Phase 1 Monotherapy Trial Of CUE-101 In HPV+ Recurrent/Metastatic Head And Neck Cancer   Benzinga
08:01AM EDT  -- CUE-101 advances to cohort 5 following Safety Review Committee assessment of expanded cohort 4 -- Cohort 5 is fully enrolled, with first patient having been dosed on July 20 -- Additional patients to be enrolled in cohort 4 to further characterize pharmacodynamics and clinical activity in support of selecting a recommended Phase 2 dose   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC